Plate Nº 36 · recorded October 10, 2026
Health & Medicine ResearchReported finding
Researchers track two pathways behind recurrent bacterial vaginosis
An Australian team has identified two pathways—reinfection and bacterial persistence—behind recurrent bacterial vaginosis, paving the way for tailored antibiotic regimens.
By Nathan Brooks3 min read658 words
In brief
- Treating male partners reduced BV recurrence in women by more than 60%, according to a 2025 New England Journal of Medicine study.
- The 2026 Lancet study identified two pathways to repeat infection: reinfection and persistence of BV-causing bacteria.
- Bacterial vaginosis is the most common vaginal condition among women of reproductive age.
- The team won the 2025 Australian Infectious Diseases Research Centre Eureka Prize for Infectious Diseases Research.
- Lead author Dr. Lenka Vodstrcil and senior author Professor Catriona Bradshaw are at Monash University and Melbourne Sexual Health Centre.
An Australian team has pinpointed two distinct pathways to recurrent bacterial vaginosis, building on a 2025 finding that treating male partners cuts recurrence in women by more than 60%.
The new analysis appears in The Lancet Obstetrics, Gynaecology & Women's Health. It comes from researchers at Monash University and Bayside Health's Melbourne Sexual Health Centre, the same group whose earlier partner-treatment study reshaped international thinking on the condition.
What is bacterial vaginosis?
Bacterial vaginosis (BV) is the most common vaginal condition among women of reproductive age. Doctors diagnose it when protective Lactobacillus bacteria decline and other microbes multiply, disrupting the vaginal microbiome, the community of bacteria that normally keeps the tissue healthy.
The condition affects millions of women worldwide and resists long-term cure in many patients. Standard antibiotic regimens work for some but leave others cycling through repeated infections.
What did the 2025 study establish?
In 2025, the same research team published a study in the New England Journal of Medicine. It showed that giving antibiotics to male partners at the same time as women reduced BV recurrence in the women by more than 60%.
The finding challenged the long-held view that BV is not sexually transmissible. It earned the team the 2025 Australian Infectious Diseases Research Centre Eureka Prize for Infectious Diseases Research.
What did the new study add?
The latest study pooled data from couples who received concurrent treatment in earlier trials. It is a post-hoc analysis, meaning researchers returned to existing datasets to look for patterns rather than testing a new regimen head-to-head.
The team identified two distinct routes to repeat infection:
- Reinfection, in which bacteria pass back from a male partner after therapy ends
- Persistence, in which BV-causing bacteria survive the initial antibiotic course and regrow inside the woman
Lead author Dr. Lenka Vodstrcil, a senior research fellow at Monash University and Bayside Health's Melbourne Sexual Health Centre, said the distinction matters for clinical decisions.
"While partner treatment improves cure for most women in a monogamous relationship, there are some women who have persistent BV bacteria that survive initial therapy before couples resume sex after treatment," Vodstrcil said.
"By identifying this early, we can intervene with more intensive female-focused treatments before the infection takes hold again."
What new treatments are being tested?
Senior author Vice-Chancellor's Distinguished Professor Catriona Bradshaw heads research translation and mentorship at Monash University and Bayside Health's Melbourne Sexual Health Centre. Her group is now testing longer antibiotic courses and new antibiotic combinations aimed at killing bacteria that survive standard therapy.
"Using partner treatment to mitigate reinfection and more intensive strategies that target persistence of BV bacteria, we hope to create more effective treatment approaches that can be tailored to an individual and achieve higher levels of cure for all women," Bradshaw said.
The aim is to match treatment to whichever pathway each patient faces, rather than applying a single course of antibiotics to everyone. These new strategies complement, rather than replace, the partner-treatment approach the same team validated in 2025.
What are the limits of the evidence?
The latest paper combines existing data rather than running a fresh randomized trial of the new regimens. The proposed antibiotic combinations therefore remain unproven until dedicated clinical trials report their findings.
The 2025 partner-treatment result also applies specifically to women in monogamous heterosexual relationships. Researchers have not yet shown whether the same approach benefits other populations, and the new two-pathway model still needs prospective testing in independent cohorts.
What comes next?
Bradshaw's team plans clinical trials of the longer and combination antibiotic regimens. If those trials confirm the strategy, tailored BV treatment could reach clinics within several years, pending regulatory review.
The study, "Determinants of repeat bacterial vaginosis in concurrently treated couples: a post-hoc pooled cohort study," appeared in The Lancet Obstetrics, Gynaecology & Women's Health (2026). DOI: 10.1016/S3050-5038(26)00259-1.
via Medical Xpress (Source)
More from Nathan Brooks
Nearby plates
- Lab-Grown 'Mini-Bladder' May Explain Why UTIs Keep Coming Back
- Scientists Map Three Weak Points in Antibiotic-Resistant Bacteria
- Gut microbes help set the body's inflammatory vaccine response
- HPV Vaccination Before Pregnancy Linked to Lower Preterm Birth Risk
- Skipping Sweets During Antibiotic Treatment May Protect Gut Microbiome